Lin J - Search Results

1

Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics.

Buenconsejo J, Liao R, Lin J, Singh P, Cooner F, Ghosh S, Gamalo M, Russek-Cohen E, Zariffa N. Buenconsejo J, et al. Among authors: lin j. Contemp Clin Trials. 2023 Sep;132:107292. doi: 10.1016/j.cct.2023.107292. Epub 2023 Jul 16. Contemp Clin Trials. 2023. PMID: 37454729

2

Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review.

Seifu Y, Gamalo-Siebers M, Barthel FM, Lin J, Qiu J, Cooner F, Ruan S, Walley R. Seifu Y, et al. Among authors: lin j. Ther Innov Regul Sci. 2020 Nov;54(6):1436-1443. doi: 10.1007/s43441-020-00170-y. Epub 2020 Jun 8. Ther Innov Regul Sci. 2020. PMID: 32514737 Review.

3

Dynamic incorporation of real world evidence within the framework of adaptive design.

Lin J, Liao R, Gamalo-Siebers M. Lin J, et al. J Biopharm Stat. 2022 Nov 2;32(6):986-998. doi: 10.1080/10543406.2022.2089159. Epub 2022 Jun 22. J Biopharm Stat. 2022. PMID: 35730907

4

Matching within a hybrid RCT/RWD: framework on associated causal estimands.

Lin J, Yu G, Gamalo M. Lin J, et al. J Biopharm Stat. 2023 Jul 4;33(4):439-451. doi: 10.1080/10543406.2022.2105346. Epub 2022 Aug 5. J Biopharm Stat. 2023. PMID: 35929973 Clinical Trial.

5

Composite Likelihoods with Bounded Weights in Extrapolation of Data.

Gamalo M, Kim Y, Zhang F, Lin J. Gamalo M, et al. Among authors: lin j. J Biopharm Stat. 2023 Nov 2;33(6):708-725. doi: 10.1080/10543406.2022.2152835. Epub 2023 Jan 20. J Biopharm Stat. 2023. PMID: 36662162

6

Extent of safety database in pediatric drug development: types of assessment, analytical precision, and pathway for extrapolation through on-target effects.

Gamalo M, Zhao Y, Gao A, Ye J, Lin J, Eshida E, Choi Y, Nelson R. Gamalo M, et al. Among authors: lin j. J Biopharm Stat. 2023 Nov 2;33(6):770-785. doi: 10.1080/10543406.2023.2172425. Epub 2023 Feb 26. J Biopharm Stat. 2023. PMID: 36843283

7

Flexible Bayesian subgroup analysis in early and confirmatory trials.

Bunn V, Liu R, Lin J, Lin J. Bunn V, et al. Among authors: lin j. Contemp Clin Trials. 2020 Nov;98:106149. doi: 10.1016/j.cct.2020.106149. Epub 2020 Sep 15. Contemp Clin Trials. 2020. PMID: 32942055 Review.

8

Ensuring exchangeability in data-based priors for a Bayesian analysis of clinical trials.

Lin J, Gamalo-Siebers M, Tiwari R. Lin J, et al. Pharm Stat. 2022 Mar;21(2):327-344. doi: 10.1002/pst.2172. Epub 2021 Sep 29. Pharm Stat. 2022. PMID: 34585501

9

A note regarding the special issue on innovative design and analysis of complex clinical trials and opportunities for future research.

Seifu Y, Gamalo-Siebers M, Lin J. Seifu Y, et al. Among authors: lin j. J Biopharm Stat. 2021 Mar;31(2):113-116. doi: 10.1080/10543406.2021.1895193. Epub 2021 Mar 7. J Biopharm Stat. 2021. PMID: 33678133 No abstract available.

10

Incorporating propensity scores for evidence synthesis under bayesian framework: review and recommendations for clinical studies.

Lin J, Lin J. Lin J, et al. J Biopharm Stat. 2022 Jan 2;32(1):53-74. doi: 10.1080/10543406.2021.1882481. Epub 2021 May 16. J Biopharm Stat. 2022. PMID: 33998364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40,493 results

Search Page

Filters